Literature DB >> 7905500

Effects of IL-12 on the response and susceptibility to experimental viral infections.

J S Orange1, S F Wolf, C A Biron.   

Abstract

Effects of administered IL-12 on immune responses to viral infection were evaluated. IL-12-mediated effects during lymphocytic choriomeningitis virus (LCMV) infection in C57BL/6 mice were contrasted to those in either uninfected mice, or mice infected with a virus inducing a more modest T cell response, murine cytomegalovirus. Mice received 0, 1, 10, 100, or 1000 ng/d of IL-12 on the day prior to infection and daily on day 0 to 6 post-infection. Responses were examined on day 7. Low doses of IL-12 enhanced immunity to LCMV infection as demonstrated by increased splenic CD8+ T cell numbers and decreased LCMV replication. Low doses of IL-12 also significantly enhanced splenic CD8+ T cell numbers in murine cytomegalovirus-infected mice. In contrast, high doses of IL-12 were detrimental to resistance against LCMV infection. Higher doses of IL-12: 1) inhibited virus-specific CTL lytic capacity per spleen by > 90%; 2) inhibited virus-induced expansion of CD8+ T cells in spleen, peripheral blood, and lymph nodes by > 80%; 3) induced necrotic lesions in splenic white pulp; and 4) resulted in 2 log increases in splenic and renal viral replication. Initiation of high dose IL-12 treatment on day 0, 1, 2, or 4 post-infection had similar effects. Although serum levels of IFN-gamma and TNF were normally not detectable in LCMV-infected mice, infection acted synergistically with IL-12 for cytokine induction. The IL-12-mediated reduction in CD8+ T cell numbers and synergistic enhancement of circulating cytokines levels observed during LCMV infection were unique to this infection. These results demonstrate that IL-12-mediated effects can be either protective or detrimental, depending upon the environment in which the factor is presented.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7905500

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  60 in total

1.  Dose-dependent and schedule-dependent effects of interleukin-12 on antigen-specific CD8 responses.

Authors:  K Lee; W W Overwijk; M O'Toole; H Swiniarski; N P Restifo; A J Dorner; S F Wolf; K Sturmhoefel
Journal:  J Interferon Cytokine Res       Date:  2000-06       Impact factor: 2.607

2.  Interleukin-12 as an adjuvant for an antischistosome vaccine consisting of adult worm antigens: protection of rats from cercarial challenge.

Authors:  R D Bungiro; M Goldberg; P K Suri; P M Knopf
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  Interleukin-12 production by human monocytes infected with Mycobacterium tuberculosis: role of phagocytosis.

Authors:  S A Fulton; J M Johnsen; S F Wolf; D S Sieburth; W H Boom
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

4.  IL-12 in conjunction with dendritic cells enhances antiviral CD8+ CTL responses in vitro.

Authors:  N Bhardwaj; R A Seder; A Reddy; M V Feldman
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

5.  Interleukin-12 exhibits potent antiviral activity in experimental herpesvirus infections.

Authors:  J A Carr; J Rogerson; M J Mulqueen; N A Roberts; R F Booth
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

6.  Multilayer polypeptide nanoscale coatings incorporating IL-12 for the prevention of biomedical device-associated infections.

Authors:  Bingyun Li; Bingbing Jiang; Brandon M Boyce; Brock A Lindsey
Journal:  Biomaterials       Date:  2009-02-12       Impact factor: 12.479

7.  Role of interleukin-12 in primary influenza virus infection.

Authors:  J M Monteiro; C Harvey; G Trinchieri
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

Review 8.  Natural pathogens of laboratory mice, rats, and rabbits and their effects on research.

Authors:  D G Baker
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

9.  Inhibition of IL-12 synthesis of peripheral blood mononuclear cells (PBMC) stimulated with a bacterial superantigen by pooled human immunoglobulin: implications for its effect on Kawasaki disease (KD).

Authors:  Y Takata; S Seki; H Dobashi; S Takeshita; K Nakatani; Y Kamezawa; H Hiraide; I Sekine; S Yoshioka
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

10.  The role of interleukin-12 in acquired immunity to Mycobacterium tuberculosis infection.

Authors:  A M Cooper; A D Roberts; E R Rhoades; J E Callahan; D M Getzy; I M Orme
Journal:  Immunology       Date:  1995-03       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.